- Home | Harrow, Inc.
Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability
- Products | Harrow, Inc.
Harrow has contracted for the U S commercial rights to BYQLOVI™, BYOOVIZ®, and OPUVIZ™ These products will be added to this section once they are launched by Harrow
- Corporate Presentation November 2025 - harrow. com
Harrow was founded to advance the standard of eye care and deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
- Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
Integration into Harrow: Melt Pharmaceuticals will be fully integrated into Harrow’s operations to ensure a seamless transition and accelerate progress toward NDA submission, approval, and market launch
- Harrow To Report Third Quarter 2025 Financial Results After Market . . .
The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow com Harrow will host a conference call and live webcast at 8:00 a m Eastern Time on Tuesday, November 11, 2025, to discuss the results and provide a business update
- Careers | Harrow, Inc.
At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together Humility, ownership, preparedness, and entrepreneurship create the foundation for a culture where initiative is celebrated, creativity thrives, and impact is real
- Investor Relations | Harrow, Inc.
Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
- 0001493152-25-012840 | 8-K | iXBRL Viewer | Harrow INC
Harrow INC SEC filing: Form 8-K iXBRL on 09 09 2025 (0001493152-25-012840)
|